Rosiglitazone and cardiovascular disease: a cardiologist's perspective

Abstract

References

1. Nissen SE , Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.

2. Home PD , Pocock SJ , Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiovascular Outcomes - An Interim Analysis. N Engl J Med 2007;epub June 5, 2007.

3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65.

4. Dormandy JA , Charbonnel B , Eckland DJA. et al. investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 2005;366:1279–89.

5. Haffner SM , Greenberg AS , Weston WM , Chen H , Williams K , Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;196:679–84.

6. Natali A , Toschi E , Baldeweg S. et al. Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. Eur Heart J 2005;26:464–71.

7. Choi D , Kim SK , Choi SH. et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 Diabetes. Diabetes Care 2004;27:2654–60.

8. Marfella R , D'Amico M , Esposito K. et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 2006;55:622–32.

9. Meisner F , Walcher D , Gizard F. et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 2006;26:845–50.

10.

10. Dagenais GR , Pogue J , Fox K , Simoons ML , Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581–8.

11.

11. Bosch J , Yusuf S , Gerstein HC. et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551–62.

12.

12. Krucoff MW , Boam A , Schultz DG.

Drug-eluting stents “deliver heartburn”: how do we spell relief going forward?

Circulation 2007;115:2990–4.